These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 10669909

  • 1. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R, Singh I, Kaur KJ, Kaul CL.
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):625-8. PubMed ID: 10669909
    [Abstract] [Full Text] [Related]

  • 2. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2004 May 19; 276(1-2):41-9. PubMed ID: 15113612
    [Abstract] [Full Text] [Related]

  • 3. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.
    Clin Ther; 2013 Feb 19; 35(2):161-8. PubMed ID: 23410999
    [Abstract] [Full Text] [Related]

  • 4. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA, Revankar SN, Bhatt AD, Vaz JA, Desai ND, D'Sa S, Shah V, Gandewar K.
    Int J Tuberc Lung Dis; 1999 Jul 19; 3(7):627-31. PubMed ID: 10423226
    [Abstract] [Full Text] [Related]

  • 5. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Clin Pharmacol Ther; 2002 Oct 19; 40(10):474-81. PubMed ID: 12395981
    [Abstract] [Full Text] [Related]

  • 6. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G, Fourie PB, Padayatchi N, Onyebujoh PC, McIlleron H, Smith PJ, Gabriels G.
    Int J Tuberc Lung Dis; 1999 Nov 19; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [Abstract] [Full Text] [Related]

  • 7. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z, Augustynowicz-Kopeć E, Niemirowska-Mikulska H.
    Acta Pol Pharm; 2002 Nov 19; 59(6):448-52. PubMed ID: 12669769
    [Abstract] [Full Text] [Related]

  • 8. Bioequivalence of isoniazid in a two drug fixed dose combination and in a single drug dosage form.
    Agrawal S, Kaul CL, Panchagnula R.
    Pharmazie; 2001 Aug 19; 56(8):636-9. PubMed ID: 11534341
    [Abstract] [Full Text] [Related]

  • 9. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2002 Feb 21; 233(1-2):169-77. PubMed ID: 11897421
    [Abstract] [Full Text] [Related]

  • 10. Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.
    Ashokraj Y, Singh I, Kaur KJ, Kohli G, Bhade SR, Varma MV, Kaul CL, Panchagnula R.
    Int J Tuberc Lung Dis; 2005 Jul 21; 9(7):791-6. PubMed ID: 16013776
    [Abstract] [Full Text] [Related]

  • 11. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H.
    Int J Tuberc Lung Dis; 1998 Oct 21; 2(10):824-30. PubMed ID: 9783530
    [Abstract] [Full Text] [Related]

  • 12. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.
    Hao LH, Guo SC, Liu CC, Zhu H, Wang B, Fu L, Chen MT, Zhou L, Chi JY, Yang W, Nie WJ, Lu Y.
    Int J Tuberc Lung Dis; 2014 Dec 21; 18(12):1505-12. PubMed ID: 25517820
    [Abstract] [Full Text] [Related]

  • 13. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.
    Int J Tuberc Lung Dis; 1999 Feb 21; 3(2):119-25. PubMed ID: 10091876
    [Abstract] [Full Text] [Related]

  • 14. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
    Panchagnula R, Kaur KJ, Singh I, Kaul CL.
    Int J Tuberc Lung Dis; 1999 Nov 21; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
    [Abstract] [Full Text] [Related]

  • 15. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA, Villalpando-Hernández J, Novoa-Heckel G, Oliva I, Cariño L, López-Bojórquez E, Burke-Fraga V, Namur S, González-de la Parra M.
    Clin Ther; 2009 Feb 21; 31(2):399-410. PubMed ID: 19302912
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
    Nyazema NZ, Rabvukwa P, Gumbo J, Ndudzo P, Chitemerere C.
    Cent Afr J Med; 1999 Jun 21; 45(6):141-4. PubMed ID: 10695183
    [Abstract] [Full Text] [Related]

  • 19. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
    Panchagnula R, Kaur KJ, Singh I, Kaul CL.
    Methods Find Exp Clin Pharmacol; 2000 Nov 21; 22(9):689-94. PubMed ID: 11294011
    [Abstract] [Full Text] [Related]

  • 20. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R, Müller FO, Duursema L, Groenewoud G, Hundt HK, Middle MV, Mogilnicka EM, Swart KJ.
    Arzneimittelforschung; 1995 Nov 21; 45(11):1236-9. PubMed ID: 8929247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.